Genmab A/S (GMAB) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Genmab (GMAB) by buying the Nasdaq-listed American Depositary Shares or fractional shares at any major broker, through a biotech or international healthcare ETF that holds it, or as one holding in a thematic basket. Genmab is a Danish antibody company whose cash flow today comes mostly from royalties on drugs other companies sell, above all DARZALEX, which Johnson & Johnson markets in multiple myeloma. The thing to understand before anything else is that management is deliberately spending that royalty stream to build wholly owned products before daratumumab's exclusivity runs out, which is what the $8 billion Merus acquisition was about.
GMAB stock price
As of 2026-11-16, Genmab A/S (GMAB) last closed at $51.57, up 69.5% over the past year. Over the past 52 weeks it has traded between $23.85 and $57.29.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Genmab A/S's investor relations page. Walnut is informational, not investment advice.
GMAB key stats
At $51.57 on November 16, 2026, Genmab A/S (GMAB) has a market cap of $31.7B and a P/E of 44.1 on trailing earnings (32.6 on forward earnings).
- Market cap
- $31.7B
- P/E (trailing)
- 44.1
- P/E (forward)
- 32.6
- EPS (trailing 12 months)
- $1.17
- Price to book
- 5.2
- Beta
- 0.52
Market cap, P/E and yield are measured at the $51.57 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Genmab A/S (GMAB)?
The last two weeks for Genmab A/S, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- GMAB closed at $51.57 on November 16, 2026, down 7.6% over the past five trading days (from $55.80).
- On November 12, 2026, Genmab A/S filed a current report (6-K) with the SEC. Read the 6-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Genmab A/S (GMAB) do?
Genmab A/S, founded in 1999 and headquartered in Copenhagen, engineers therapeutic antibodies and has historically licensed them to larger partners rather than selling them itself. The best known is daratumumab, sold by Johnson & Johnson as DARZALEX and DARZALEX FASPRO, which has become a backbone therapy in multiple myeloma and pays Genmab a royalty on worldwide net sales. Genmab also earns royalties on ofatumumab (Kesimpta, Novartis) and teprotumumab (TEPEZZA), and shares in two commercial products it helped develop: epcoritamab, sold as EPKINLY in the US and TEPKINLY in Europe with AbbVie, and tisotumab vedotin (TIVDAK) with Pfizer. The strategic shift under way is toward owning products outright. Rina-S (rinatabart sesutecan), a folate receptor alpha antibody-drug conjugate in ovarian cancer, is wholly owned, and the December 2025 close of the $8 billion all-cash acquisition of Merus N.V. at $97 per share added petosemtamab, a late-stage bispecific in head and neck cancer.
As of October 16, 2026 the ADSs closed around $37.50, up about 18% year to date and about 15% over the past year, for a market capitalization near $23.1 billion against trailing twelve-month revenue of roughly $4.1 billion. First-half 2026 revenue grew about 25% to roughly $2.05 billion, operating profit was about $555 million, and adjusted operating profit about $656 million. DARZALEX royalties were roughly $1.31 billion in the half, up about 20%, on worldwide DARZALEX net trade sales of about $4.21 billion in the second quarter alone. EPKINLY and TEPKINLY net sales reached about $312 million in the half, up about 48%, and TIVDAK about $84 million. Management raised full-year 2026 guidance to revenue of about $4.33 billion to $4.53 billion and adjusted operating profit of about $1.07 billion to $1.39 billion. The number that frames everything else is concentration: DARZALEX royalties alone were roughly 64% of first-half revenue, which is why the market spends more time on the pipeline than on the current income statement. Note that US investors buy an ADS rather than the Copenhagen-listed ordinary share, and that Genmab presents its financial statements in US dollars even though the ordinary shares trade in Danish kroner.
Two things have moved the story since the first-half report. On October 6, 2026 Genmab and AbbVie said a Phase 3 trial adding EPKINLY to standard R-CHOP chemotherapy in newly diagnosed, intermediate- or high-risk diffuse large B-cell lymphoma cut the risk of progression or death by 51% versus R-CHOP plus placebo. The companies plan to discuss the results with regulators and present them at a future medical meeting, and the shares rose as much as 14% that day. On October 13 Genmab reported that worldwide DARZALEX net trade sales reached about $4.24 billion in the third quarter of 2026, a small step up from the second quarter. Full third-quarter results are expected around November 5, 2026.
What's driving Genmab A/S (GMAB)?
1. DARZALEX royalties still compounding.
Daratumumab keeps taking share in multiple myeloma, moving earlier into treatment lines and into subcutaneous dosing, and worldwide net trade sales reached about $4.21 billion in the second quarter of 2026 and about $4.24 billion in the third. Genmab's royalty on that stream rose about 20% year over year in the first half to roughly $1.31 billion. It requires almost no spending from Genmab, which is what funds the rest of the company.
2. EPKINLY as the first real commercial franchise.
Epcoritamab, a CD3 by CD20 bispecific for B-cell lymphomas, grew net sales about 48% year over year to roughly $312 million in the first half of 2026 and was cited by management as a driver of the raised guidance. Genmab shares the economics with AbbVie rather than keeping them all. The frontline question got a large answer in October 2026: a Phase 3 trial of EPKINLY plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma reduced the risk of progression or death by 51% against R-CHOP alone. If regulators accept the data, epcoritamab would move from a later-line drug into the largest lymphoma treatment setting, and the remaining contest with the two Roche bispecifics is about how fast that label arrives and how widely it is used.
3. The wholly owned late-stage pipeline: Rina-S and petosemtamab.
Rina-S is a folate receptor alpha antibody-drug conjugate in registrational work in ovarian cancer, with combination data also being pursued. Petosemtamab, acquired with Merus, is a bispecific in head and neck squamous cell carcinoma that carries breakthrough designation. Both are owned outright, so a success would land at a far better margin than a royalty or a profit share, and both carry the binary clinical and regulatory risk that comes with that.
4. Capital redeployment ahead of the daratumumab cliff.
Paying $8 billion in cash for Merus was an explicit choice to convert a royalty balance sheet into owned late-stage assets while the royalty is still large. It substantially reduced the cash position and raises the cost of a clinical failure. Genmab has also been buying back and cancelling shares, including the cancellation of 1.9 million treasury shares approved at the March 2026 annual general meeting.
5. Q3 2026 results expected in early November.
Genmab's next report is expected around November 5, 2026. It beat the EPS consensus in Q2 2026 ($0.49 per ADS against $0.33) after missing in Q4 2025 and Q1 2026, so the run of results has been uneven quarter to quarter even as revenue climbed about 25%. Analysts expect about $1.17 of 2026 EPS per ADS and about $1.51 in 2027, with the 2026 figure held down by the costs of the Merus deal.
What are the risks to Genmab A/S (GMAB)?
Revenue concentration is the first-order risk: DARZALEX royalties were roughly 64% of first-half 2026 revenue, Genmab does not control how the drug is priced or promoted, and daratumumab exclusivity does not last forever, so the whole equity story is a race between pipeline conversion and eventual biosimilar erosion. Multiple myeloma is also the most crowded field in oncology, with Sanofi's Sarclisa, Pfizer's Elrexfio, and Johnson & Johnson's own TECVAYLI, TALVEY, and CARVYKTI all competing for the same patients that daratumumab treats. EPKINLY faces Roche's Lunsumio and Columvi and Regeneron's odronextamab in lymphoma, and Rina-S enters an ovarian setting where AbbVie's Elahere is already established. The wholly owned pipeline concentrates outcome risk in a small number of readouts, and the Merus deal spent a large share of the balance sheet on one of them: Genmab now carries about $5.3 billion of debt against roughly $1.5 billion of cash. The frontline DLBCL success also raises the bar, since the stock now prices in a label expansion that regulators have not yet granted. AbbVie has also filed a trade secret misappropriation complaint in US federal court touching antibody-drug conjugate technology, which is separate from ordinary commercial risk. Finally, the ADS carries Danish krone exposure and the ordinary share's Copenhagen listing sets the price the ADS tracks.
What is the Genmab A/S (GMAB) forecast?
10 analysts publish price targets on GMAB, averaging $65.11 as of November 2026, or +26.3% against the $51.57 share price on November 16, 2026. The published targets run from $48.00 to $80.00, a moderate spread, and the ratings split 10 buy, 2 hold, 0 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full GMAB forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is GMAB a buy or a sell?
We give no verdict on Genmab A/S. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. DARZALEX royalties still compounding. Daratumumab keeps taking share in multiple myeloma, moving earlier into treatment lines and into subcutaneous dosing, and worldwide net trade sales reached about $4.21 billion in the second quarter of 2026 and about $4.24 billion in the third. The most optimistic published target, $80.00, assumes this works close to its best case.
The case against. Revenue concentration is the first-order risk: DARZALEX royalties were roughly 64% of first-half 2026 revenue, Genmab does not control how the drug is priced or promoted, and daratumumab exclusivity does not last forever, so the whole equity story is a race between pipeline conversion and eventual biosimilar erosion. The most pessimistic target, $48.00, is roughly what GMAB is worth if this bites instead.
Read the full bull and bear case on GMAB, including what would have to change to break either one. Walnut is not an investment adviser.
Has Genmab A/S (GMAB) split its stock?
Yes. Genmab A/S (GMAB) has had one share split in the last 10 years:
- 5:1 on May 1, 2018, so every share held became 5 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of GMAB the day before the 5:1 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Genmab A/S (GMAB) valued?
Market cap, P/E and dividend yield at today's price are in the GMAB key stats above. The business figures below come from Genmab A/S's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$4.1 billion, presented in US dollars (up ~25% year over year in Q2 2026)
- DARZALEX net trade sales (Q3 2026): ~$4.24 billion worldwide, on which Genmab earns a royalty
- Margins (TTM): ~93% gross, ~35% operating, ~19% net
- 2026 guidance (raised August 2026): Revenue ~$4.33 billion to ~$4.53 billion; adjusted operating profit ~$1.07 billion to ~$1.39 billion
As of October 2026: Figures are approximate and tied to the asOf date; verify live numbers before acting. Genmab is consistently profitable because the royalty line carries almost no cost, but trailing net income of about $788 million now absorbs the interest and operating costs of the Merus acquisition, which is why earnings fell while revenue grew about 25%. After rising about 32% over three months on the frontline EPKINLY data, the ADS trades near 5.6x sales and about 25x forward earnings, so the multiple now carries more pipeline expectation than it did in the summer.
Which ETFs hold Genmab A/S (GMAB)?
If you want GMAB exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.
| ETF | Name | % in GMAB | Expense ratio | |
|---|---|---|---|---|
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 3.75% | 0.55% |
Who competes with Genmab A/S (GMAB)?
Multiple myeloma competitors around the DARZALEX franchise
Sanofi's Sarclisa is the other anti-CD38 antibody, Pfizer's Elrexfio and Johnson & Johnson's TECVAYLI and TALVEY are bispecifics, and CAR-T therapies such as CARVYKTI and Abecma compete for later-line patients. The relationship here is unusual: Johnson & Johnson is simultaneously Genmab's largest royalty payer through DARZALEX and the developer of several therapies that could displace it. Anything that shifts myeloma treatment away from a daratumumab backbone reduces Genmab's largest revenue line without Genmab having any operational lever to respond.
T-cell engaging bispecifics in lymphoma
Roche's Lunsumio (mosunetuzumab) and Columvi (glofitamab) and Regeneron's odronextamab target the same CD20-positive B-cell lymphomas as EPKINLY, with similar mechanisms and overlapping trial programs. Competition here is about label breadth, line of therapy, safety and administration convenience rather than novelty, since the class is now established. Genmab shares EPKINLY economics with AbbVie, so share gains flow through at a lower rate than they would for a wholly owned drug.
Antibody-drug conjugate developers
AbbVie's Elahere is the incumbent folate receptor alpha ADC in ovarian cancer and the direct comparator for Rina-S, while Daiichi Sankyo with AstraZeneca (Enhertu, Datroway), Pfizer through Seagen, and Gilead (Trodelvy) set the pace for the wider class. ADCs are where much of oncology's development capital is going, which raises both the odds of a competing readout and the cost of running the trials. AbbVie's trade secret complaint against Genmab sits inside this same technology area.
What stocks are similar to Genmab A/S (GMAB)?
Other names that sit close to GMAB: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Genmab A/S (GMAB)
There are three common ways to get GMAB exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FBT), which spreads the position across many companies. Or build it into a focused thematic portfolio, so GMAB sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where GMAB fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Genmab A/S (GMAB)
As of October 2026, Genmab is a profitable, royalty-funded antibody developer trading around 5.6x trailing revenue after an October rally on frontline lymphoma data for EPKINLY, whose value turns on whether EPKINLY, Rina-S, and petosemtamab can replace DARZALEX royalties before those royalties start to fade.
More on Genmab A/S (GMAB)
Whether GMAB is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GMAB a buy or a sell?, and where the stock could go from here in the GMAB stock forecast.
For income investors, whether GMAB pays a dividend and how the payout looks is covered in does GMAB pay a dividend? And to weigh GMAB against a peer, read the full side-by-side comparisons: GMAB vs SNY and GMAB vs PFE.
Wondering how GMAB fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Genmab A/S
Ask Walnut's AI anything about GMAB and see how it fits what you own.
FAQ
Is GMAB a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The case for it is a profitable royalty engine growing about 20%, raised 2026 guidance, EPKINLY sales up about 48%, a positive Phase 3 frontline lymphoma readout for EPKINLY in October 2026, and two wholly owned late-stage assets in Rina-S and petosemtamab. The case against it is that roughly 64% of first-half revenue came from royalties on a drug Genmab does not sell, exclusivity on that drug is finite, the $8 billion Merus deal concentrated a lot of the balance sheet behind a small number of clinical readouts, and after a roughly 32% three-month rally the ADS trades near 25x forward earnings.
What does Genmab actually do?
+
It designs therapeutic antibodies, mostly for cancer, using its own platforms such as DuoBody for bispecifics and HexaBody for enhanced antibody activity. Historically it licensed those antibodies to larger pharmaceutical companies and collected royalties, which is how DARZALEX ended up being sold by Johnson & Johnson. More recently it has been building products it owns and commercializes itself, which is the strategic shift the Merus acquisition was meant to accelerate.
How do US investors buy Genmab, and what is the ADS ratio?
+
Genmab's ordinary shares trade in Copenhagen in Danish kroner, and US investors typically buy the American Depositary Shares listed on Nasdaq under GMAB. The ADR program's ratio is ten ADSs to one ordinary share, so an ADS represents a tenth of the Copenhagen-listed share and trades at roughly a tenth of its price. Because that ratio was changed, per-ADS prices from earlier periods are not directly comparable to today's without adjustment. Confirm the current ratio with your broker or the company's ADR program page before doing per-share math.
Where does Genmab's revenue actually come from?
+
Mostly royalties. DARZALEX royalties were about $1.31 billion of roughly $2.05 billion in first-half 2026 revenue, with additional royalties on Kesimpta and TEPEZZA. Product sales are still the smaller piece: EPKINLY and TEPKINLY contributed about $312 million and TIVDAK about $84 million in the same period. The whole investment question is how quickly that mix shifts toward products Genmab owns.
What happens when DARZALEX loses exclusivity?
+
Daratumumab's patent protection runs out at different times in different markets, and biosimilar competition would erode the royalty rather than end it overnight, particularly given the shift toward the subcutaneous FASPRO formulation. Genmab has been explicit that it is investing ahead of that point, which is the stated logic for the Merus purchase and the wholly owned pipeline. The risk is one of timing: if EPKINLY, Rina-S, and petosemtamab ramp more slowly than the royalty declines, revenue growth stalls in between.
Why did Genmab buy Merus?
+
For petosemtamab, a bispecific antibody targeting EGFR and LGR5 in head and neck squamous cell carcinoma that had breakthrough therapy designation and was in late-stage development. Genmab announced the roughly $8 billion all-cash deal at $97 per Merus share in late 2025, completed the tender offer in December 2025, and framed it as accelerating into a wholly owned commercial model. It was funded largely with cash and debt, so it materially changed the balance sheet.
Does Genmab pay a dividend?
+
Genmab has not historically paid a regular dividend, directing cash into research, acquisitions, and share repurchases instead. Its 2026 annual general meeting approved cancelling 1.9 million treasury shares acquired through buybacks. Holders should treat GMAB as a growth holding rather than an income one, and check the company's latest disclosures for any change in capital return policy.
What are the main risks of investing in GMAB?
+
Concentration in DARZALEX royalties, which Genmab neither prices nor promotes and which faces eventual biosimilar competition. Crowded competition in myeloma from Sarclisa, Elrexfio, TECVAYLI, TALVEY, and CAR-T therapies, and in lymphoma from Roche's Lunsumio and Columvi. Binary clinical and regulatory risk on Rina-S and petosemtamab, now amplified because $8 billion of cash went into acquiring one of them. An AbbVie trade secret complaint in US court touching antibody-drug conjugate technology. And the mechanical points that the ADS carries Danish krone exposure and tracks a Copenhagen listing.
What did the October 2026 EPKINLY lymphoma trial show?
+
Genmab and AbbVie reported on October 6, 2026 that adding EPKINLY (epcoritamab) to R-CHOP chemotherapy in newly diagnosed diffuse large B-cell lymphoma, in patients at intermediate or high risk, reduced the risk of disease progression or death by 51% compared with R-CHOP plus placebo. The companies said they will discuss the data with regulators and present it at a future medical meeting. Frontline DLBCL is a much larger setting than the later-line use EPKINLY is approved for today, though Genmab shares the economics with AbbVie.
How has GMAB stock performed in 2026?
+
As of October 16, 2026 the ADS closed near $37.50, up about 18% year to date and about 15% over the past year, with a 52-week range of roughly $23.62 to $40.17. Most of the gain came in the last three months (up about 32%), driven by the frontline EPKINLY readout and continued DARZALEX royalty growth. The 11 analysts tracked by Yahoo Finance have a mean target of about $44.40. Walnut is not an investment adviser.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Genmab A/S's investor relations page or your broker before making investment decisions.